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the TRUE Dilatation™ Balloon Valvuloplasty Catheter in patients undergoing transcath-
eter aortic valve implantation (TAVI).
Methods: Between January and May 2012, a total of 18 patients (pts) with high grade
aortic stenosis underwent valvuloplasty of the aortic valve using the TRUE Dilatation™
Balloon Valvuloplasty Catheter prior to TAVI. Several performance measures were
evaluated and graded from 1 to 10, which 10 indicating best performance.
Results: Subjects were 83 6 years old, logistic EuroSCORE 16 7%, STS 9.6 4.5.
The mean aortic gradient was 4819mmHg, the valve orifice area was 0.66 0.19 cm2.
BAV was successful in all cases. Neither balloon nor annular rupture occurred in any
case,. Balloon inflation and deflation times were less than 2 seconds, The grade for the
performance measure “ease of catheter insertion through introducer sheath” was 9.30.5
points, 9.10.5 for “ease of passing catheter over aortic arch, ease of catheter crossing
over aortic valve” 9.20.7 points, for “speed of balloon inflation” 9.60.6 points, for
“ability to dilate aortic valve without balloon slippage” 8.91.7 points, and for “speed of
balloon deflation” 8.91.1 points. Five pts (28%) received and Edwards SAPIEN XT and
12 pts (72%) a Medtronic CoreValve Prosthesis after BAV. The 30 day stroke and
mortality rates were zero and 5.6%.
Conclusions: This study shows that the TRUE Dilatation™ Balloon Valvuloplasty
Catheter has an excellent performance with fast inflation and deflation times in patients
with severe aortic stenosis in the absence of harmful side effects.
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Background: Transcatheter aortic valve implantation (TAVI) procedures offer remark-
able benefits for high risk patients with severe aortic stenosis. However, the current TAVI
devices are associated with complications such as lack of repositionability, paravalvular
leakage and atrio-ventricular block. Moreover, there is no long-term clinical data about the
durability of current tissue-derived TAVI prostheses and leaflet degradation during the
loading into the catheter remains a serious concern.
Methods: A new generation transcatheter aortic valve (TAV) has been developed by our
group at University College London. The UCL-TAV benefits from leaflets made of a
novel nanocomposite polymer encompassed by a self-expandable Nitinol stent. The
polymer is composed of a polycarbonate urea urethane soft segment (PCU) and hard
segment derived from polyhedral oligomeric silsesquioxane (POSS) nanoparticles
through covalent bonding forming pendant chain functional groups. POSS-PCU nano-
composite possesses enhanced physiochemical properties, resistance to calcification and
thrombosis with superior in-vivo biostability. It has been successfully implanted in human
in the form of a small calibre bypass graft, lacrimal duct conduit, and more recently as the
world’s first synthetic trachea. The UCL-TAV design allows for multi-stage expansion of
the prosthesis providing controlled deployment, and is fully retrievable in the case of
misplacement.
Results: POSS-PCU demonstrated superior mechanical properties compared to porcine
and bovine pericardial tissues. Initial prototypes of UCL-TAV were successfully pro-
duced using a consistent manufacturing technique, and tested for collapse and re-
expansion over several cycles with no observable structural damage. Owing to its thin
polymeric leaflets membrane, the valve can be crimped in to a catheter equal to or less
than 18 Fr to provide easier vascular access, and the design has improved anchoring and
sealing with no need for excessive radial force.
Conclusions: Having a fully retrievable design as well as an advanced material, the
UCL-TAV can overcome the main limitations of current TAVI devices. The UCL-TAV
is currently under pre-clinical evaluation.
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Background: Percutaneous tricuspid valve implantation has received little attention,
mainly due to the unstructured annulus and the associated difficult stentframe anchoring.
Tricuspid regurgitation is commonly a result of right ventricle-dilation secondary to left
heart diseases. A novel anatomically adapted tricuspid heart valve prosthesis, consisting
of a vena cava superior-stent (CSA) and a tricuspid annulus-stent (ASA) connected by
flexible struts, was developed. Anatomical CT-data of a porcine heart (65 kg, female) was
post-processed using Mimics and 3-matic (Materialise, Leuven, Belgium) and relevant
dimensions were considered in the stent design process. The anchoring of the prosthesis
relies primarily on the CSA-stent and is supported by the valved ASA-stent. First
experience with this anchoring concept, using a design with an additional vena cava
inferior-stent, was gained in animal trials which demonstrated the feasibility of the
concept.
Methods: Finite element simulations were performed with Abaqus (Simulia, Providence,
USA) to analyze the crimping process of the arched stent-construct and the loading on a
straight catheter. A custom trileaflet heart valve was sewn into the 40 mm diameter
ASA-stent, using bovine and porcine pericardium for the leaflets and a sealing skirt,
respectively. The smallest diameter was determined by crimping tests and a catheter was
adapted. The physiological function of the new prosthesis sample was tested in-vitro
inside a mock-loop, specifically designed for the simulation of the right heart. The valved
stent-construct was introduced into an anatomical silicone-model of the right heart to
analyze the adaptation to the heart structure and the prosthesis’ function in-vitro.
Results: The arched stent-construct of a vena cava superior-stent, five struts and a large
valved tricuspid annulus-stent could be crimped to fit the custom delivery catheter system.
The in-vitro tests showed good adaptation, enough flexibility of the struts, good seal and
a physiological pressure of 5/40 mmHg was applied.
Conclusions: The percutaneous tricuspid valve approach was proven to work with two
different designs, one already assessed in animal trials and one successful in in-vitro tests.
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Background: Revalving failed bioprostheses with transcatheter valves cannot be done
routinely because of diminished EOA and concerns for their long-term durability. A
two-part rapidly exchangeable tissue valve has been developed as an alternative. The
design of the valve was inspired by the off-patent features of the Edwards Perimount/
Magna series. It is a two-component valve where the permanent base can be implanted
without the leaflets, improving visibility and hence speed of implant. The removable
leaflet set can later be exchanged via transapical access, off-pump.
Methods: Animal studies have shown calcification resistance superior to the Perimount,
and bench studies show greater EOA than the Magna, and durability greater than 200
million cycles at a closing pressure of 200 mmHg. In its first clinical use, 23-mm size
valves were implanted into three men, two with bicuspid valves and one with senile aortic
valve stenosis. Two were placed with infra-annular pledgets and one with supra-annular
pledgets. The base was inserted first and then the leaflet set was attached with the aid of
clear plastic shields that protected the 2-mm high post.
Results: Placement of the base first allowed easier valve insertion, as tall commissural
posts, found in current pericardial valves were not present to obstruct suture tying.
Furthermore, the absence of leaflets allowed additional infra-valvular sutures to be placed
without difficulty.
Conclusions: This new valve shows promise for easier insertion and good durability. In
addition it may facilitate leaflet-set exchange, should it deteriorate later. Further study
appears to be justified for early and late results.
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Background: A pre-hospital electrocardiogram (ECG) improves the management of
patients with ST-segment elevation myocardial infarction (STEMI). Current telecommu-
nication systems do not permit real-time interaction with first responders in the field or
with care providers at referring hospitals. Our institution has developed a novel
telecommunications system based on a software application that is downloadable to
multiple platforms to permit real-time, two-way video and voice interaction over a
secured, HIPPA compliant network.
Methods: We hypothesized that the use of the CodeHeart application (CHap) for patients
with possible acute coronary syndrome will reduce door-to-balloon (DTB) times of
STEMI patients. Therefore, all STEMI system activations after implementation of the
CHap system, were prospectively entered into a database. Consecutive CHap activations
were compared to routine activations as controls, during the same time period (03/14/2011
to 12/31/2011). System quality measures were calculated and compared using Student’s
t test or the Mann-Whitney U test as appropriate.
Results: A total of 360 STEMI system activations occurred. 62 (17%) employed CHap
and 298 (83%) routine channels. DTB times were reduced by the use of CHap when
compared to controls (95.335’ vs. 154.6102.4’, p0.0009) as were first call-to-
balloon times (68.929.3’ vs. 91.740’, p0.004), which highlights our network’s
response efficiency for transferred patients. The percentage of catheterization laboratory
activations for a true STEMI was higher with the use of CHap, although this trend did not
reach statistical significance. [CHap 38/62 (61.3%) vs. routine 148/298 (49.7%), p0.12].
Conclusions: The implementation of a two-way telecommunications system that allows
for real-time interactions between interventional cardiologists and referring practitioners
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